Latest & greatest articles for Cancer Prevention

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Cancer Prevention or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Cancer Prevention and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Cancer Prevention

1. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. (PubMed)

Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Platinum-based therapy, including cisplatin, carboplatin, oxaliplatin or a combination of these, is used to treat a variety of paediatric malignancies. One of the most significant adverse effects is the occurrence of hearing loss or ototoxicity. In an effort to prevent this ototoxicity, different otoprotective medical interventions have been studied. This review is the third update of a previously (...) published Cochrane Review.To assess the efficacy of medical interventions to prevent hearing loss and to determine possible effects of these interventions on antitumour efficacy, toxicities other than hearing loss and quality of life in children with cancer treated with platinum-based therapy as compared to placebo, no additional treatment or another protective medical intervention.We searched the Cochrane Central Register of Controlled Trials, MEDLINE (PubMed) and Embase (Ovid) to 8 January 2019. We

2019 Cochrane

2. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer

Clinical practice guidelines for the prevention, early detection and management of colorectal cancer Clinical practice guidelines for the prevention, early detection and management of colorectal cancer - Cancer Guidelines Wiki Skip Links Personal tools Search Navigation Cancer Council guidelines Methodology Hosted cancer guidelines Adolescents and Young Adult (AYA) guidelines Prevention Policies Social links Page actions The guideline recommendations were approved by the Chief Executive Officer (...) , and developed for health professionals practising in an Australian health care setting. This publication reflects the views of the authors and not necessarily the views of the Australian Government. Cite this guideline Cancer Council Australia Colorectal Referring to the large bowel, comprising the colon and rectum. Cancer Guidelines Working Party. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer. Sydney: Cancer Council Australia. [Version URL: , cited

2019 Cancer Council Australia

3. Interim: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer

Interim: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer 1 Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer Interim Guidance from the Kaiser Permanente National Integrated Cardiovascular Health (ICVH) Work Group October 5, 2018 Three randomized clinical trials (ARRIVE 1 , ASCEND 2 , and ASPREE 3 ) recently published results on aspirin use in patients without known Atherosclerotic Cardiovascular Disease (ASCVD). The studies looked at benefits including (...) cardiovascular event prevention, and risks including serious bleeding events. Overall the studies suggest that aspirin lacks net benefit (total benefits minus total harms) beyond age 70, and there is low net benefit in younger adults. USPSTF 2016 aspirin recommendations point to highest net benefit for aspirin in adults age 50-59 (lower bleeding risk than older patients) with 10-year ASCVD risk* >10%. The National Kaiser Permanente Aspirin recommendations will be formally updated following a comprehensive

2019 Kaiser Permanente National Guideline Program

4. Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention

Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention - ACOG Menu ▼ Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention Page Navigation ▼ Number 774 (Replaces Committee Opinion Number 620, January 2015) Committee on Gynecologic Practice This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee (...) by representatives of the other organizations are addressed by those organizations. The American College of Obstetricians and Gynecologists has neither solicited nor accepted any commercial involvement in the development of the content of this published product. Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention ABSTRACT: Opportunistic salpingectomy may offer obstetrician–gynecologists and other health care providers the opportunity to decrease the risk of ovarian cancer

2019 American College of Obstetricians and Gynecologists

5. Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients. (PubMed)

Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients. Pulmonary complications are often seen during the postoperative period following lung resection for patients with lung cancer. Some situations such as intubation, a long stay in the intensive care unit, the high cost of antibiotics and mortality may be avoided with the prevention of postoperative pulmonary complications. Non-invasive positive pressure ventilation (NIPPV (...) ) is widely used in hospitals, and is thought to reduce the number of pulmonary complications and mortality after this type of surgery. Therefore, a systematic review is needed to critically assess the benefits and harms of NIPPV for patients undergoing lung resection. This is an update of a Cochrane review first published in 2015.To assess the effectiveness and safety of NIPPV for preventing complications in patients following pulmonary resection for lung cancer.We searched the Cochrane Central Register

2019 Cochrane

6. Surgical interventions for the prevention or treatment of lymphoedema after breast cancer treatment. (PubMed)

Surgical interventions for the prevention or treatment of lymphoedema after breast cancer treatment. Breast cancer is the most common type of cancer amongst women worldwide, and one distressing complication of breast cancer treatment is breast and upper-limb lymphoedema. There is uncertainty regarding the effectiveness of surgical interventions in both the prevention and management of lymphoedema affecting the arm after breast cancer treatment.1. To assess and compare the efficacy of surgical (...) interventions for the prevention of the development of lymphoedema (LE) in the arm after breast cancer treatment.2. To assess and compare the efficacy of surgical interventions for the treatment of established LE in the arm after breast cancer treatment.We searched the Cochrane Breast Cancer Group's Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the WHO International Clinical Trials Registry

2019 Cochrane

7. Common osteoporosis drugs may prevent breast cancer spreading to bone

Common osteoporosis drugs may prevent breast cancer spreading to bone Common osteoporosis drugs may prevent breast cancer spreading to bone Discover Portal Discover Portal Common osteoporosis drugs may prevent breast cancer spreading to bone Published on 13 March 2018 doi: Drugs commonly prescribed to prevent bone thinning probably help prevent the spread of early breast cancer to the bones in a few women, when taken in addition to standard cancer therapies. However, the overall benefits may (...) be small, for example preventing spread to bone or death in about one extra woman in every 100 treated for about five years. This is a complex area because many of the treatments for breast cancer are known to worsen bone thinning, but there are other bone strengthening benefits to these drugs. This large review of 44 studies with more than 37,000 participants looked at women with either early breast cancer or advanced breast cancer with or without bone involvement. The reviewers also concluded

2019 NIHR Dissemination Centre

8. The effect of probiotics for the prevention or treatment of cancer therapy (chemotherapy or radiotherapy) -induced oral mucositis: a systematic review and meta-analysis

The effect of probiotics for the prevention or treatment of cancer therapy (chemotherapy or radiotherapy) -induced oral mucositis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

9. The comparative efficacy and safety of novel oral anticoagulants, warfarin and low molecular weight heparin in patients with cancer to prevent venous thromboembolism: a network meta-analysis

The comparative efficacy and safety of novel oral anticoagulants, warfarin and low molecular weight heparin in patients with cancer to prevent venous thromboembolism: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

10. The effectiveness of mHealth interventions for cervical cancer prevention among women in high income countries

The effectiveness of mHealth interventions for cervical cancer prevention among women in high income countries Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

11. Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients

Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

12. Prevention of breast and cervical cancer in refugees and asylum seekers: a systematic review and meta-analysis

Prevention of breast and cervical cancer in refugees and asylum seekers: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

13. Systematic review of aspirin in the prevention of hereditary and sporadic colorectal adenoma and cancer

Systematic review of aspirin in the prevention of hereditary and sporadic colorectal adenoma and cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

14. Direct oral anticoagulant (DOAC) versus placebo for the prevention of thrombosis in ambulatory patients with cancer at increased risk: a systematic review and meta-analysis

Direct oral anticoagulant (DOAC) versus placebo for the prevention of thrombosis in ambulatory patients with cancer at increased risk: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

15. Overview of systematic reviews of non-pharmacological interventions for preventing and treating chemotherapy-induced peripheral neuropathy in cancer patients

Overview of systematic reviews of non-pharmacological interventions for preventing and treating chemotherapy-induced peripheral neuropathy in cancer patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

16. A systematic review and meta-analysis of the efficacy of rectal washout in preventing local recurrence after anterior resection for rectal cancer

A systematic review and meta-analysis of the efficacy of rectal washout in preventing local recurrence after anterior resection for rectal cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

17. Effectiveness of various invitation methods to a colonoscopy in the early detection and prevention of colorectal cancer

Effectiveness of various invitation methods to a colonoscopy in the early detection and prevention of colorectal cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

18. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. (PubMed)

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. Patients with active cancer have an increased risk of venous thromboembolism, which results in substantial morbidity, mortality, and health care expenditures. The Khorana score (range, 0 to 6, with higher scores indicating a higher risk of venous thromboembolism) has been validated to identify patients with cancer at elevated risk for this complication and may help select those who could benefit from thromboprophylaxis.We (...) conducted a randomized, placebo-controlled, double-blind clinical trial assessing the efficacy and safety of apixaban (2.5 mg twice daily) for thromboprophylaxis in ambulatory patients with cancer who were at intermediate-to-high risk for venous thromboembolism (Khorana score, ≥2) and were initiating chemotherapy. The primary efficacy outcome was objectively documented venous thromboembolism over a follow-up period of 180 days. The main safety outcome was a major bleeding episode.Of the 574 patients who

2018 NEJM

19. Fosaprepitant (IVEMEND) - prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy

Fosaprepitant (IVEMEND) - prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy Fosaprepitant (IVEMEND ® ). Reference number 3789. Page 1 of 3 AWMSG Secretariat Assessment Report – Limited submission Fosaprepitant (IVEMEND ® ) 150 mg powder for solution for infusion Company: Merck Sharp & Dohme Ltd Licensed indication under consideration: Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy (...) to be of minimal budgetary impact. Clinical effectiveness ? Fosaprepitant has been in use in Wales for adults since 2009. It did not meet the criteria for appraisal by the All Wales Medicines Strategy Group (AWMSG), as its marketing authorisation date for the adult population was granted before 1 October 2010. This submission considers a licence extension for fosaprepitant for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients aged from 6

2018 All Wales Medicines Strategy Group

20. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. (PubMed)

Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. It is unclear whether supplementation with vitamin D reduces the risk of cancer or cardiovascular disease, and data from randomized trials are limited.We conducted a nationwide, randomized, placebo-controlled trial, with a two-by-two factorial design, of vitamin D3 (cholecalciferol) at a dose of 2000 IU per day and marine n-3 (also called omega-3) fatty acids at a dose of 1 g per day for the prevention of cancer (...) and cardiovascular disease among men 50 years of age or older and women 55 years of age or older in the United States. Primary end points were invasive cancer of any type and major cardiovascular events (a composite of myocardial infarction, stroke, or death from cardiovascular causes). Secondary end points included site-specific cancers, death from cancer, and additional cardiovascular events. This article reports the results of the comparison of vitamin D with placebo.A total of 25,871 participants, including

2018 NEJM